The two peptides that dominate every recovery conversation, almost always mentioned as a pair. TB-500 scores meaningfully higher, but the more important fact is what they share: neither has real human trial evidence behind it.
Start with what the shared numbers say. Both compounds score just 5 out of 25 on study design, because both are studied almost entirely in animal and in vitro models with essentially no controlled human trials. That single shared fact is more important than the 21-point gap: people cross-shop these as if picking between two proven recovery tools, when both are actually early-stage on human evidence.
TB-500's higher total comes from journal impact factor, funding independence, and replication, its preclinical literature is somewhat broader and published in stronger journals. That earns it Limited over BPC-157's Weak, but Limited is still a long way from established.
BPC-157 has the larger community following and the louder anecdotal reputation, which is exactly the gap this comparison exists to surface: its popularity runs well ahead of its human research. TB-500 is the better-evidenced of the two on paper, but neither has the controlled human data that would move it into Moderate or Strong.
The real decision here is not "BPC-157 or TB-500." It is recognizing that both sit at a similar early evidence stage, TB-500 marginally ahead, and that choosing between them is a choice between two compounds whose human research is largely still to come. Their low scores reflect that absence of human data, not a verdict on whether the animal findings will hold up.